On December 14, 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com), ("Provectus" or the "Company"), a clinical-stage biotechnology company developing a novel therapeutic platform based on halogenated xanthenes for the treatment of multiple diseases, including cancer and inflammatory dermatoses, reported the United States Patent and Trademark Office (the "USPTO") has granted U.S. patent ("USP") 9,839,688 for the combination of intralesional ("IL") PV-10 with systemic immunomodulatory therapy, including anti-PD-1 and anti-PD-L1 agents, for the treatment of solid tumor cancers (Press release, Provectus Pharmaceuticals, DEC 14, 2017, View Source [SID1234522643]). This new patent is a continuation of USP 9,107,887, Provectus’ first cancer combination therapy patent granted by the USPTO in 2015, and is related to USP 9,808,524, the Company’s second cancer combination therapy patent granted by the USPTO in November 2017. Pfizer, Inc. is a co-assignee on all three patents.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Know more, wherever you are:
Latest on Combination Therapies in Oncology, book your free 1stOncology demo here.
Dominic Rodrigues, Chairman of the Company’s Board of Directors, said, "This third patent represents our further efforts to increase the potential commercial value of Provectus’ clinical development program in cancer combination therapy. Notably, the new addition to this part of the Company’s patent estate includes coverage for multiple solid tumor cancers that are already in our research and development pipeline."
Mr. Rodrigues added, "Over time, Provectus and our research and clinical collaborators have jointly or independently shown, on a preclinical or clinical basis, the combination of PV-10 and another class of agent or therapy, including checkpoint inhibition, chemotherapy, and radiation, in multiple cancer indications, including hepatocellular carcinoma, melanoma and pancreatic cancer. These data have been presented at conferences of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) and Society for Melanoma Research, and published in the Journal of Surgical Oncology, and Melanoma Research."